Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157209
Status:
COMPLETED
Last Update Posted:
2015-11-18
First Post:
2005-09-08
Brief Title:
Phase 2b Randomized Controlled Study of Tecemotide L-BLP25 for Immunotherapy of NSCLC Non-Small Cell Lung Cancer
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Organization Data
Organization:
Merck KGaA Darmstadt Germany
Class:
INDUSTRY
Study ID:
B25-LG-304 EMR 63325-005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck KGaA Darmstadt Germany
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None